small molecule

OMNARIS

CICLESONIDE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyAZURITY PHARMACEUTICALS INC

Drug detail

Brand nameOMNARIS
Active ingredientCICLESONIDE
Strength0.05MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalOctober 2006
Marketing statusRX

Listed patents

PatentExpiresType
8371292February 2028use U-1356

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OMNARIS patent cliff — loss of exclusivity February 2028 | CliffBio